— Know what they know.
Not Investment Advice

AKYA NASDAQ

Akoya Biosciences, Inc.
1W: +0.0% 1M: +4.9% 3M: +3.2% 1Y: -44.2% 3Y: -90.5%
$1.29
Last traded 2025-07-16 — delisted
NASDAQ · Healthcare · Medical - Instruments & Supplies · $64.4M mcap · 13M float · 4.62% daily turnover · Short 13% of daily vol

Balance Sheet Trends

Total Assets
$125M -30.7% ▼
5Y CAGR: +6.9%
Total Liabilities
$117M -7.3% ▼
5Y CAGR: -0.4%
Shareholders Equity
$8M -85.9% ▼
Cash & Investments
$35M -57.8% ▼
5Y CAGR: +10.1%
Total Debt
$84M -1.8% ▼
5Y CAGR: +27.7%
Net Debt
$72M +2703.8% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2020FY2021FY2022FY2023FY2024
— Assets —
Cash$17M$113M$74M$83M$12M
Short-Term Investments$0$0$7M$0$23M
Cash & ST Investments$17M$113M$81M$83M$35M
Net Receivables$6M$9M$10M$17M$14M
Inventory$4M$9M$14M$18M$24M
Other Current Assets$0$0$7M$4M$4M
Total Current Assets$29M$141M$112M$122M$77M
Property, Plant & Equip.$6M$7M$22M$21M$13M
Goodwill & Intangibles$41M$39M$38M$36M$33M
Long-Term Investments$502K$302K$303K$699K$0
Other Non-Current Assets$2M$3M$3M$2M$2M
Total Non-Current Assets$49M$50M$64M$59M$48M
Total Assets$78M$191M$176M$180M$125M
— Liabilities —
Accounts Payable$5M$9M$11M$12M$9M
Short-Term Debt$1M$272K$0$0$3M
Deferred Revenue$4M$4M$6M$7M$7M
Other Current Liabilities$5M$7M$8M$6M$3M
Total Current Liabilities$17M$28M$37M$35M$29M
Long-Term Debt$33M$32M$63M$75M$76M
Other Non-Current Liab.$7M$8M$6M$6M$4M
Total Non-Current Liabilities$42M$42M$80M$91M$88M
Total Liabilities$59M$70M$117M$127M$117M
— Equity —
Common Stock$1K$2K$2K$2K$2K
Retained Earnings-$52M-$96M-$167M-$230M-$285M
Accumulated OCI$0$0-$6K$0$7K
Total Stockholders Equity$18M$121M$59M$54M$8M
Total Liabilities & Equity$78M$191M$176M$180M$125M
— Key Metrics —
Total Debt$35M$33M$76M$86M$84M
Net Debt$18M-$81M$2M$3M$72M
Total Investments$502K$302K$7M$699K$23M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms